MitoSense, a Plymouth, MA-based research and development company focused on neurodegenerative disease treatments, raised $3.5M in Seed funding.
The round was led by Caydan Capital Partners.
The company intends to use the funds to advance its innovative work in Mitochondria Organelle Transplantation (MOT™️).
MitoSense is a biotechnology company dedicated to advancing mitochondrial health through innovative therapies and research, focusing on treatments for neurodegenerative diseases. This technology has broad potential applications in treating Alzheimer’s, Parkinson’s, Huntington’s, Multiple Sclerosis, and other neurodegenerative diseases.
In addition to its Series Seed funding round, MitoSense is also supported by the following organizations, whose collaborations are pivotal to its success:
- Elliott Mitochondrial Research Center: Enhancing mitochondrial research capabilities.
- James A. Haley Veterans’ Hospital: Developing therapies for neurodegenerative dysfunctions in veterans.
- Walter Reed Army Institute of Research: Focusing on mitochondrial health in military personnel.
- Greenwood Genetic Center: Researching Alzheimer’s Diseases and genetic aspects of mitochondrial diseases.
- Uppsala University, Sweden, Center for Advanced Medicinal Products: Evolving patient accessible advanced medicinal products from cellular starting materials.
FinSMEs
22/01/2024